Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
This study tests whether measuring how tumor cells respond to weight or mass changes can help doctors quickly predict which treatments will work best for patients with malignant pleural effusion (fluid around the lungs caused by cancer). Researchers will use tumor cells collected from patients to test different therapies and see if this new biomarker can guide treatment decisions faster.
Key Objective: This trial is testing whether a new biomarker based on tumor cell mass response can help doctors rapidly identify the most effective therapies for individual patients.
Who to Consider: Patients with malignant pleural effusion who are interested in contributing to research that could improve how doctors select personalized cancer treatments should consider enrolling.
Trial Parameters
Brief Summary
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Eligibility Criteria
Inclusion Criteria: 1. Patient is ≥18 years of age 2. Written Informed Consent provided by patient 3. Diagnosis of any kind of carcinoma 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC 5. Proceeding onto therapy for treatment 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088) Exclusion Criteria: 1. Lack of informed consent 2. Unable to obtain sufficient sample